11th Annual MassBio Investors Forum
Tuesday, October 6 2009
11th Annual MassBio Investors Forum
Tue, October 6
Agenda subject to change, please visit website for regular updates
7:30am: Registration Opens
8:00am: Partnering Meetings and Company Presentations begin and will run throughout the day
8:00 – 8:45am: How to Leverage NCI SBIR Dollars to Move Your Technology to Commercialization — $12 Million in New Funding Opportunities Now Available
Michael Weingarten, Director of the NCI SBIR Development Center
The National Cancer Institute’s SBIR program just announced 23 new funding opportunities to take your cancer research to the next level. This is an exclusive opportunity for you to learn how you can tap into one of the largest sources of early stage non dilutive funding in the country. The Director of NCI’s SBIR Program will also discuss the new SBIR Bridge Award, a unique $3 million funding opportunity to accelerate promising cancer related technologies to commercialization. NCI will be available for one-on-one meetings with both companies and investors.
9:00 – 9:20am: Welcome Remarks
- Lt. Governor Timothy P. Murray
- Robert Coughlin, President & CEO, MassBio
- Mark Leuchtenberger, Chairman, MassBio
9:20 – 10:50am: Morning Plenary –A Sustainable Biotech Business Model
Moderator: Ted Torphy, CSO & Head, External Research, Johnson & Johnson
Join us as we bring key stakeholders from pharma, biotech and venture capital and focus on how to promote better collaboration and alignment between the three.
This panel will also look to the biotech companies involved, to provide actionable advice to delegates regarding the most critical elements of a sustainable biotech business model.
- Katrine Bosley, Chief Executive Officer, Avila Therapeutics
- Alan Crane, General Partner, Polaris Venture Partners
- Barry Greene, President and Chief Operating Officer, Alnylam Pharmaceuticals, Inc.
- James J. O'Mara, Vice President, Business Development, Ironwood Pharmaceuticals, Inc.
- Noubar Afeyan, PhD, Managing Partner and CEO, Flagship Ventures
10:50 – 11:10am: Break
11:10am – 12:20pm: Panel Discussion – Disease Foundations and Venture Capital: Can the two "play in the same sandbox?"
Moderator: Vaughn M. Kailian, Managing Director, MPM Capital, LLC
Disease foundations are investing and biotech companies are now collaborating with both venture and foundations. As these relationships deepen and become more prevalent, companies must learn how to work with both investors, and demonstrate value creation for all stakeholders — furthering possible cures and a positive rate of return. Can this really work?
This panel will feature disease foundations with companies they work with answering questions posed by the VC and pharma community:
- How are exit strategies addressed by disease foundations when a company is not achieving critical milestones?
- What are the different stages in development that disease foundations examine when deciding to invest?
- How can biotech companies satisfy investors with two different endgames operating on two different timelines?
- What are the common touch points for these stakeholders?
- Timothy Coetzee, Ph.D., President, Fast Forward, LLC
- Louis J. DeGennaro, Ph.D., Chief Scientific Officer, The Leukemia & Lymphoma Society (LLS)
- Bharat Tewarie, MD, MBA, Vice President, Head of Business Development USA , Head of Global Business Development Endocrinology/Fertility, EMD Serono Inc.
- Richard A. Insel, M.D., Executive Vice President, Research, Juvenile Diabetes Research Foundation
- Scott Jackson, R.Ph., M.B.A., Chief Executive Officer, Celator Pharmaceuticals
- Douglas J. Ringler, VMD, Cofounder, President & Chief Executive Officer, Tolerx
12:20 – 1:10pm: Networking Luncheon
1:15 – 2:45pm: Moderated Joint Q&A with Steve Burrill and Gary Pisano:
- Steven Burrill, CEO, Burrill & Company, and
- Gary Pisano, Harry E. Figgie, Jr. Professor of Business Administration, Harvard Business School, and author of Science Business: The Promise, The Reality and The Future of Biotech
Moderator: Lawrence Wittenberg, Partner, Goodwin Procter, LLP
2:45 – 3:15pm: Break
Signing of Memorandum of Understanding (MOU) between MassBio and the United Kingdom’s Golden Triangle Partnership:
This ceremony demonstrates the commitment of both groups to foster collaboration in the ever-growing global economy. The Golden Triangle Partnership is comprised of the Cambridge, London and Oxford bioclusters. Participants include British Consul-General to New England, Dr. Philip Budden, Executive Director of the Massachusetts Office of International Trade and Investment Ted Carr, and President & CEO of MassDevelopment Robert Culver.
3:15 – 4:30pm: Panel Discussion – Strategic Alliances
Moderator: Reid J. Leonard, Ph.D., Executive Director, Licensing And External Research, Merck & Co., Inc.
Topics discussed by the panel will include:
- How to identify the best partner for your company
- The types of partnerships offered by larger companies, and how to determine if your company is a candidate for an investment, license, or an M&A
- The best strategies for securing a strategic investment or alliance
- How strategic investment differs from VC investment
- The importance of deal structure and key contract terms
- The pros and cons of an investment or alliance with a larger company
- The do's and don'ts in prospecting for the deal, negotiating the deal, and managing the relationship
- Maggie Flanagan LeFlore, Ph.D., Managing Director, MedImmune Ventures
- Mike Diem, Partner, SR One
- Barbara Dalton, Vice President, Pfizer Venture Investments (PVI)
- Ed Torres, Managing Director, Lilly Ventures
- Cat Oyler, Sr. Director, Emerging Technologies Office of Science and Technology, Johnson & Johnson
4:30 – 6:15pm: Reception